Several trials evaluating this combination strategy are ongoing, such as the BEVERLY trial to evaluate the efficacy of erlotinib plus bevacizumab or erlotinib in advanced NSCLC with sensitive EGFR mutations in the first-line setting. Here, EGFR is linked to non-small cell lung carcinoma.